PerkinElmer/Caliper Life Sciences
On September 8, 2011, PerkinElmer, Inc. (NYSE: PKI), has signed a definitive agreement to acquire Caliper Life Sciences, Inc. (Nasdaq: CALP), for $10.50 per share, for a total net purchase price of approximately $600 million in cash.
The acquisition has received the unanimous support of the Boards of Directors of both companies, and is expected to close in Q411.
The transaction is expected to be dilutive to PerkinElmer’s 2012 GAAP earnings per share by approximately 5 cents and accretive to PerkinElmer’s 2012 First Call consensus adjusted earnings per share by approximately 8 cents.
Bank of America Merrill Lynch and Rothschild acted as financial advisors to PerkinElmer. Perella Weinberg Partners acted as exclusive financial advisor to Caliper Life Sciences, Inc., and provided a fairness opinion to the Caliper Life Sciences Board of Directors.
Caliper is a Hopkinton, MA-based leader in imaging and detection solutions for life sciences research, diagnostics and environmental markets.
The acquisition has received the unanimous support of the Boards of Directors of both companies, and is expected to close in Q411.
The transaction is expected to be dilutive to PerkinElmer’s 2012 GAAP earnings per share by approximately 5 cents and accretive to PerkinElmer’s 2012 First Call consensus adjusted earnings per share by approximately 8 cents.
Bank of America Merrill Lynch and Rothschild acted as financial advisors to PerkinElmer. Perella Weinberg Partners acted as exclusive financial advisor to Caliper Life Sciences, Inc., and provided a fairness opinion to the Caliper Life Sciences Board of Directors.
Caliper is a Hopkinton, MA-based leader in imaging and detection solutions for life sciences research, diagnostics and environmental markets.
